Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3502 |
Name | ampulla of Vater adenocarcinoma |
Definition | An ampulla of Vater carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer small intestine cancer duodenum cancer ampulla of Vater cancer ampulla of Vater carcinoma ampulla of Vater adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MLH1 negative | Pembrolizumab | ampulla of Vater adenocarcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | ampulla of Vater adenocarcinoma | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | ampulla of Vater adenocarcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | ampulla of Vater adenocarcinoma | sensitive | detail... |
MSH6 negative | Ipilimumab + Nivolumab | ampulla of Vater adenocarcinoma | sensitive | detail... |
MLH1 negative | Ipilimumab + Nivolumab | ampulla of Vater adenocarcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | ampulla of Vater adenocarcinoma | sensitive | detail... |
RET fusion | Selpercatinib | ampulla of Vater adenocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01202409 | Phase II | Panitumumab | CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | Completed | USA | 0 |
NCT01208103 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin | Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | Completed | USA | 0 |
NCT02711553 | Phase II | Ramucirumab Merestinib Cisplatin + Gemcitabine | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | USA | TUR | SWE | HUN | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG | 4 |
NCT03801915 | Phase II | MVT-5873 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | Completed | USA | 0 |
NCT04163900 | Phase III | Cisplatin + NUC-1031 Cisplatin + Gemcitabine | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer (NuTide:121) | Terminated | USA | TUR | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 4 |
NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUS | 5 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |